annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 49D Trends in survival for metastatic soft-tissue sarcoma: A French Sarcoma
Group (GSF) database analysis. (Abstract #10045)
A. Italiano, S. Mathoulin-Pelissier, P. Terrier, A. Le Cesne, S. Bonvalot, F. Collin,
J. Michels, J. Blay, J. Coindre, N. Bin Bui, French Sarcoma Group GSF-GETO
Brd. 49E Novel reconstruction using tumor-containing autologous bone grafts frozen
in liquid nitrogen. (Abstract #10046)
H. Tsuchiya, K. Hayashi, T. Shirai, H. Nishida, A. Takeuchi, S. Miwa,
R. M. Hoffman
Brd. 49F Long-term follow-up of patients with GIST undergoing metastasectomy in the
era of imatinib (IM). (Abstract #10047)
B. Nguyen, F. Grabellus, M. Hoiczyk, G. Taeger, M. H. Schuler, S. Bauer
Brd. 49G Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001)
with imatinib in imatinib-resistant patients (pts) with advanced GIST.
(Abstract #10048^)
P. Hohenberger, S. Bauer, V. Gruenwald, J. T. Hartmann, E. Jaeger,
O. G. Ottmann, C. Hosius, C. May, A. Pustowka, P. Reichardt
Brd. 49H Targeting CHK1 pathway to induce cytotoxic response to histone deactylase
inhibitors and evaluating the synergistic effects of CHK1 and HDAC
inhibitors in human soft tissue sarcoma cell lines and primary tumor
xenografts. (Abstract #10049)
D. R. Reed, W. Brazelle, J. Gemmer, S. Altiok
Brd. 50A CSPG4 and B7-H3 as prognostic biomarkers in chordoma. (Abstract #10050)
A. Schoenfeld, G. P. Nielsen, F. Hornicek, Z. Duan, S. Ferrone, J. H. Schwab
Brd. 50B Outcome of patients (pts) with PDGFRA D842V mutant gastrointestinal
stromal tumor (GIST) treated with imatinib (IM) for advanced disease.
(Abstract #10051)
P. Biron, P. A. Cassier, E. Fumagalli, A. Blesius, M. Debiec-Rychter, A. Adenis,
J. Verweij, P. Hohenberger, J. Blay, P. G. Casali, EORTC Soft Tissue and Bone
Sarcoma Group
Brd. 50C Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor
(DT): Case series of 22 patients. (Abstract #10052)
A. G. Dumont, L. Rink, M. Miettinen, H. Joensuu, J. R. Strosberg, A. Gronchi,
C. L. Corless, A. J. Lazar, D. Lev, M. von Mehren
Brd. 50D Pattern of recurrence in patients with ruptured primary gastrointestinal
stromal tumor (GIST). (Abstract #10053)
O. Oladeji, E. Wardelmann, U. Ronellenfitsch, D. Pink, P. Reichardt, P. Ströbel,
P. Hohenberger
Brd. 50E Development of a nomogram to predict overall survival in patients with
locally advanced or metastatic gastrointestinal stromal tumor receiving
first-line treatment with imatinib. (Abstract #10054)
D. Goldstein, C. Lee, Y. Hui, B. Shah, D. Yip, G. A. McArthur
Brd. 50F Gastrointestinal stromal tumor (GIST) of the rectum and pararectal space: A
French Sarcoma Group (FSG) retrospective review. (Abstract #10055)
F. Duffaud, P. A. Cassier, A. Adenis, O. Bouche, M. Rios Sr., O. Collard,
E. Bompas, S. Chabaud, J. Blay, A. Le Cesne
Brd. 50G Surgery of residual disease of myxoid liposarcoma (MLS) patients
responding to trabectedin. (Abstract #10056)
R. Sanfilippo, F. Grosso, M. D’Incalci, P. Dileo, S. Pilotti, C. Morosi, M. Fiore,
J. C. Tercero, A. Gronchi, P. G. Casali
Brd. 50H Quality of randomized controlled trials reporting in the treatment of
sarcomas. (Abstract #10057)
M. Toulmonde, C. Bellera, S. Mathoulin-Pelissier, N. Bin Bui, A. Italiano
281
SUNDAY